Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Thiotepa × CNS × Clear all

Phase

Phase 2 19 Phase 1 6 Phase 3 5 Phase NA 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5 Myeloid 3 Lymphoid 2 Breast 2 Sarcoma 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Recurrence 1 Medulloblastoma 1 Ependymoma 1 Brain Neoplasms 1

Interventions

Temozolomide 10 Lomustine 5 Radiotherapy 3 Etoposide 3 Bevacizumab 3 vocimagene amiretrorepvec 2 Radiation 2 Magnetic Resonance Spectroscopy 2 Gefitinib 2 Carboplatin 2 veliparib 1 trofosfamide 1 trametinib 1 tozuleristide 1 regorafenib 1 dabrafenib 1 cobimetinib 1 carbon-11 acetate 1 antisecretory factor 1 Vorinostat 1 Vincristine 1 Vemurafenib 1 Thiotepa 1 Sunitinib 1 Standard of Care 1 Saline Solution 1 Procarbazine 1 Pregabalin 1 Melphalan 1 Lamotrigine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00749723 2018-07-20

HIT-REZ-2005

University Hospital, Bonn

Phase 2/3 Completed

Brain Neoplasms, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡